Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.

This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.

In a retrospective analysis, a team found that an algorithm integrating the gene expression of a tumor with the radiation dose a patient received predicted how well the patient responded to the treatment.

In the last decade, researchers have come to realize that tumors harbor bits of extrachromosomal DNA that can drive malignancy.

Researchers are uncovering how circular bits of DNA found in some cancer cells can help tumors evolve and kill.

The Harvard Medical School researcher’s work on the genetic basis of protein coding and production led him to make groundbreaking discoveries in immunology, molecular biology, and cancer genetics.

In the largest study of its kind to date, researchers find more than 850 rare, heritable genetic alterations that can predispose humans to cancer.

At the University of California, Santa Cruz, the researcher combs the cancer genome, looking for weaknesses.

The tumor biologist’s landmark discovery provided the first clear evidence that genetic mutations could lead to cancer, and gave rise to a crucial cancer drug.

Systems-biology approaches offer new strategies for finding hard-to-identify drug targets for cancer.

Mutations in a cancer gene could account for some cases of disfiguring blood vessel abnormalities, scientists show.

Researchers are taking advantage of small, transparent zebrafish embryos and larvae—and a special strain of see-through adults—to understand the development and spread of cancer.

A novel liquid laser set-up can detect single nucleotide mutations in a cancer gene.

A guided tour through the main online resources for analyzing cancer genomics data

A new study shows that breast cancers that become resistant to hormone therapy have different patterns of estrogen receptor binding.

A rundown of tools on the market and in development